Design, synthesis, computational study and cytotoxic evaluation of some new quinazoline derivatives containing pyrimidine moiety.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 09 2023
02 09 2023
Historique:
received:
05
04
2023
accepted:
28
08
2023
medline:
5
9
2023
pubmed:
3
9
2023
entrez:
2
9
2023
Statut:
epublish
Résumé
Quinazoline derivatives, as an important category of heterocyclic compounds, have received much attention for the design and development of new drugs due to their various pharmacological properties. Besides, there is a great deal of evidence showing pyrimidine analogs as anticancer agents. Thus, in the present study, for the design of new target compounds with cytotoxic activity, we focused on various quinazolinone and pyrimidine hybrids. A new series of quinazoline-pyrimidine hybrid derivatives (6a-6n) have been designed and synthesized as novel antiproliferative agents. All the synthesized compounds characterized based on their IR, NMR and Mass spectroscopic data. Antiproliferative activities of the new compounds were evaluated against three human cancer cell lines (MCF-7, A549, SW-480). The compounds were found to have appropriate potential with IC
Identifiants
pubmed: 37660139
doi: 10.1038/s41598-023-41530-6
pii: 10.1038/s41598-023-41530-6
pmc: PMC10475017
doi:
Substances chimiques
Quinazolines
0
Pyrimidines
0
Antineoplastic Agents
0
Antimetabolites
0
Quinazolinones
0
Antihypertensive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14461Informations de copyright
© 2023. Springer Nature Limited.
Références
Almansour, A. I. et al. Design, synthesis and antiproliferative activity of decarbonyl luotonin analogues. Eur. J. Med. Chem. 138, 932–941 (2017).
pubmed: 28753517
Bieberich, A. A. et al. Optimization of the 4-anilinoquin (az) oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform. Sci. Rep. 12, 12820 (2022).
pubmed: 35896603
pmcid: 9329436
Binkhathlan, Z. & Lavasanifar, A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives. Curr. Cancer Drug Targets 13, 326–346 (2013).
pubmed: 23369096
Kostova, I. Ruthenium complexes as anticancer agents. Curr. Med. Chem. 13, 1085–1107 (2006).
pubmed: 16611086
Hosseinzadeh, Z., Ramazani, A. & Razzaghi-Asl, N. Anti-cancer nitrogen-containing heterocyclic compounds. Curr. Org. Chem. 22, 2256–2279 (2018).
Hameed, A. et al. Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent review (2011–2016). Exp. Opin. Ther. Pat. 28, 281–297 (2018).
Karan, R., Agarwal, P., Sinha, M. & Mahato, N. Recent advances on quinazoline derivatives: A potential bioactive scaffold in medicinal chemistry. Chem. Eng. 5, 73 (2021).
He, D. et al. Pharmaceutical prospects of naturally occurring quinazolinone and its derivatives. Fitoterapia 119, 136–149 (2017).
pubmed: 28495308
Auti, P. S., George, G. & Paul, A. T. Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids. RSC Adv. 10, 41353–41392 (2020).
pubmed: 35516563
pmcid: 9057921
Emami, L., Sabet, R., Khabnadideh, S., Faghih, Z. & Thayori, P. Quinazoline analogues as cytotoxic agents; QSAR, docking, and in silico studies. Res. Pharm. Sci. 16, 528 (2021).
pubmed: 34522200
pmcid: 8407157
Divar, M., Zomorodian, K., Bastan, S., Yazdanpanah, S. & Khabnadideh, S. Synthesis of some quinazolinone derivatives using magnetic nanoparticles-supported tungstic acid as antimicrobial agents. J. Iran. Chem. Soc. 15, 1457–1466 (2018).
Faghih, Z. et al. Synthesis of some novel dibromo-2-arylquinazolinone derivatives as cytotoxic agents. Res. Pharm. Sci. 14, 115 (2019).
pubmed: 31620187
pmcid: 6791173
Ismail, R. S., Ismail, N. S., Abuserii, S. & Abou El Ella, D. A. Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents. Fut. J. Pharm. Sci. 2, 9–19 (2016).
Eldehna, W. M. et al. Design, synthesis, in vitro biological assessment and molecular modeling insights for novel 3-(naphthalen-1-yl)-4, 5-dihydropyrazoles as anticancer agents with potential EGFR inhibitory activity. Sci. Rep. 12, 12821 (2022).
pubmed: 35896557
pmcid: 9329325
Mass, R. D. The HER receptor family: A rich target for therapeutic development. Int. J. Radiat. Oncol. Biol. Phys. 58, 932–940 (2004).
pubmed: 14967453
Baselga, J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7, 2–8 (2002).
pubmed: 12202782
Greig, S. L. Osimertinib: First global approval. Drugs 76, 263–273 (2016).
pubmed: 26729184
Piotrowska, Z. et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 5, 713–722 (2015).
pubmed: 25934077
pmcid: 4497836
Kim, D.-W. et al. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Lung Cancer 135, 66–72 (2019).
pubmed: 31447004
Zu, G., Chen, J., Song, B. & Hu, D. Synthesis, anti-tomato spotted wilt virus activities, and interaction mechanisms of novel dithioacetal derivatives containing a 4 (3 H)-Quinazolinone pyrimidine ring. J. Agric. Food Chem. 69, 14459–14466 (2021).
pubmed: 34807587
Xu, Z., Zhao, S.-J. & Liu, Y. 1, 2, 3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. Eur. J. Med. Chem. 183, 111700 (2019).
pubmed: 31546197
Misra, A. et al. Synthesis, biological evaluation and molecular docking of pyrimidine and quinazoline derivatives of 1, 5-benzodiazepine as potential anticancer agents. J. King Saud Univ. Sci. 32, 1486–1495 (2020).
Emami, L. et al. Design, synthesis, molecular simulation, and biological activities of novel quinazolinone-pyrimidine hybrid derivatives as dipeptidyl peptidase-4 inhibitors and anticancer agents. New J. Chem. 44, 19515–19531 (2020).
Moasser, M. M. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26, 6577–6592 (2007).
pubmed: 17486079
pmcid: 3071580
Geyer, C. E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733–2743 (2006).
pubmed: 17192538
Ayati, A. et al. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg. Chem. 99, 103811 (2020).
pubmed: 32278207
Barker, A. J. et al. Studies leading to the identification of ZD1839 (Iressa™): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11, 1911–1914 (2001).
pubmed: 11459659
Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239–246 (2012).
pubmed: 22285168
Wedge, S. R. et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Can. Res. 62, 4645–4655 (2002).
Planchard, D. et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29, 192–237 (2018).
Zare, S., Ramezani, Z., Ghadiri, A. A. & Fereidoonnezhad, M. Synthesis of N-(2-(tert-Butylamino)-2-oxoethyl)-2, 2-dichloro-N-aryl (alkyl) acetamides as anticancer agents: molecular modeling and biological evaluations. Chem. Select 8, e202203931 (2023).
Khanal, P. et al. Integration of system biology tools to investigate huperzine A as an anti-Alzheimer agent. Front. Pharmacol. 56, 3362 (2021).
Sargazi, S. et al. 8-Alkylmercaptocaffeine derivatives: Antioxidant, molecular docking, and in-vitro cytotoxicity studies. Bioorg. Chem. 111, 104900 (2021).
pubmed: 33894429
Zargari, F. et al. Study of tyramine-binding mechanism and insecticidal activity of oil extracted from Eucalyptus against Sitophilus oryzae. Front. Chem. 10, 15–123 (2022).
Zare, S., Fereidoonnezhad, M., Afshar, D. & Ramezani, Z. A comparative QSAR analysis and molecular docking studies of phenyl piperidine derivatives as potent dual NK1R antagonists/serotonin transporter (SERT) inhibitors. Comput. Biol. Chem. 67, 22–37 (2017).
pubmed: 28043073
Alessandrini, S., Gauss, J. R. & Puzzarini, C. Accuracy of rotational parameters predicted by high-level quantum-chemical calculations: Case study of sulfur-containing molecules of astrochemical interest. J. Chem. Theory Comput. 14, 5360–5371 (2018).
pubmed: 30141928
Wang, W., Wolf, R. J., Caldwell, J. W. & Kollman, P. A. Case. DA J. Comput. Chem. 25, 92 (2004).
Jakalian, A., Bush, B. L., Jack, D. B. & Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I method. J. Comput. Chem. 21, 132–146 (2000).
Mark, P. & Nilsson, L. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. J. Phys. Chem. A 105, 9954–9960 (2001).
Case, D. A. et al. AMBER 22 Reference Manual. (2022).
Essmann, U. et al. A smooth particle mesh Ewald method. J. Chem. Phys. 103, 8577–8593 (1995).
Hess, B., Bekker, H., Berendsen, H. J. & Fraaije, J. G. LINCS: A linear constraint solver for molecular simulations. J. Comput. Chem. 18, 1463–1472 (1997).
Coveney, P. V. & Wan, S. On the calculation of equilibrium thermodynamic properties from molecular dynamics. Phys. Chem. Chem. Phys. 18, 30236–30240 (2016).
pubmed: 27165501
Knapp, B., Ospina, L. & Deane, C. M. Avoiding false positive conclusions in molecular simulation: The importance of replicas. J. Chem. Theory Comput. 14, 6127–6138 (2018).
pubmed: 30354113
Wan, S., Sinclair, R. C. & Coveney, P. V. Uncertainty quantification in classical molecular dynamics. Phil. Trans. R. Soc. A 379, 20200082 (2021).
pubmed: 33775140
pmcid: 8059622
Wan, S., Knapp, B., Wright, D. W., Deane, C. M. & Coveney, P. V. Rapid, precise, and reproducible prediction of peptide–MHC binding affinities from molecular dynamics that correlate well with experiment. J. Chem. Theory Comput. 11, 3346–3356 (2015).
pubmed: 26575768
Bhati, A. P., Wan, S., Wright, D. W. & Coveney, P. V. Rapid, accurate, precise, and reliable relative free energy prediction using ensemble based thermodynamic integration. J. Chem. Theory Comput. 13, 210–222 (2017).
pubmed: 27997169
Wan, S. et al. Rapid and reliable binding affinity prediction of bromodomain inhibitors: A computational study. J. Chem. Theory Comput. 13, 784–795 (2017).
pubmed: 28005370
Kiani, Y. S., Ranaghan, K. E., Jabeen, I. & Mulholland, A. J. Molecular dynamics simulation framework to probe the binding hypothesis of CYP3A4 inhibitors. Int. J. Mol. Sci. 20(18), 4468 (2019).
pubmed: 31510073
pmcid: 6769491
Paris, R. D., Quevedo, C. V., Ruiz, D. D., Souza, O. N. D. & Barros, R. C. Clustering molecular dynamics trajectories for optimizing docking experiments. Comput. Intell. Neurosci. 2015, 32–32 (2015).